Price History

Hover for the daily close. The dotted line marks the period open.

Compare OVID with… →

OVID Key Statistics

As of Sep 4, 2026

Trading

Open: $2.74
Previous Close: $2.78
Day's Range: 2.71–2.83
52-Week Range: 1.12–3.11
Volume: 1.07M
Beta: 0.25

Valuation

Market Cap: $546.83M
P/E Ratio: unprofitable
P/S ratio: 345.44
EPS (ttm): −0.21

Financials (FY)

Revenue (FY): $7.25M+1181.27%
Net Income (FY): −$17.41M
Profit margin: 0.00%
Shares Outstanding: 195.30M
1-Year Return: +117.05%

Dividend and dates

Earnings Date: November 11, 2026estimated
Avg Volume: 2.28M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OVID Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−75.48%+74.52%+71.78%

2017*201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+71.78%
2025	+74.52%
2024	−70.99%
2023	+73.12%
2022	−42.06%
2021	+38.96%
2020	−44.34%
2019	+71.49%
2018	−75.48%
2017 (partial year)	−19.43%

As of September 4, 2026.

OVID Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$7.25M	−$17.41M	−240.1%
2024	$566.00K	−$26.43M	−4670.1%
2023	$392.00K	−$52.34M	−13351.8%
2022	$1.50M	−$54.17M	−3604.7%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$7.25M	—	−$42.44M	−$17.41M	−240.1%
2024	$566.00K	—	−$61.89M	−$26.43M	−4670.1%
2023	$392.00K	—	−$59.28M	−$52.34M	−13351.8%
2022	$1.50M	—	−$55.55M	−$54.17M	−3604.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OVID Valuation vs Biotechnology Median

Median of 656 stocks

Metric	OVID	Biotechnology median	vs median
P/S ratio	345.44	15.26	22.6x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ovid Therapeutics Inc. (OVID) is capitalised at $546.83M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 23 employees.

The 52-week range on file runs from $1.12 to $3.11. The most recent close on file for OVID is $2.80, dated September 4, 2026. That is +$0.02 (+0.72%) against the previous close. The latest close sits 150% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $7.25M. Against the prior fiscal year total of $566.00K, that is a change of +1,181.27%. The same year closed with a net loss of $17.41M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.21.

Across the 4 fiscal years on file, revenue moves from $1.50M in 2022 to $7.25M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 345.44. On price-to-sales that is 22.6 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.25. Annualized volatility over the trailing 9 years is 84.41%. The trailing one-year price return is +117.05%. Measured over 5 years, that is −4.42% a year compounded.

Growth & Income

No dividend is on file for OVID.

So far in 2026 the price is +71.78%. The strongest complete calendar year on file is 2025 at +74.52%; the weakest is 2018 at −75.48%. Of the 8 complete calendar years on file, 4 finished higher.

Peer Comparison

Ovid Therapeutics Inc. (OVID) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Ovid Therapeutics Inc.	OVID	$546.83M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Ovid Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Visit website →

Ovid Therapeutics Inc. (OVID) Stock Analysis